"label","id","instanceType","rationale","uuid:ID","name","description"
"","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","d65852bf-bbab-4ce6-863e-2222a72cc5da","Study Design 1","The main design for the study"
